跳转至内容

尊敬的客户：

目前国际形势复杂多变，关税政策尚不明朗，这可能对我们的产品价格产生一定影响。在此情况下，我们希望就订单事宜与您进行友好沟通。

基于当前的不确定性，如果您选择在此期间下单，我们将保留根据实际情况调整价格的权利。同时，我们也理解市场变化可能给您带来的困扰，因此如果在订单实际发货前因关税政策变动导致价格出现较大波动，默克将与您进行协商讨论并视情况对订单进行调整或取消。

Merck
CN
所有图片(1)

主要文件

查看所有文档

N0850000

尼莫地平

European Pharmacopoeia (EP) Reference Standard

别名:

1,4-二氢-2,6-二甲基-4-（3-硝基苯基）-3,5-吡啶二甲酸-2-甲氧基乙基1-甲基乙基酯, 1,4-二氢-2,6-二甲基-4-（间硝基苯基）-3,5-吡啶二甲酸异丙酯-2-甲氧基乙酯

登录查看公司和协议定价

选择尺寸

18 L
¥3,876.66

¥3,876.66

请联系客服了解存货情况
获取大包装报价
所有图片(1)

选择尺寸

变更视图
18 L
¥3,876.66

About This Item

经验公式（希尔记法）:
C21H26N2O7
CAS号:
66085-59-4
分子量:
418.44
MDL编号:
MFCD00153848
UNSPSC代码:
41116107
PubChem化学物质编号:
329818466
NACRES:
NA.24

¥3,876.66

请联系客服了解存货情况
获取大包装报价

等级

pharmaceutical primary standard

API类

nimodipine

制造商/商品名称

EDQM

应用

pharmaceutical (small molecule)

包装形式

neat

SMILES字符串

COCCOC(=O)C1=C(C)NC(C)=C(C1c2cccc(c2)[N+]([O-])=O)C(=O)OC(C)C

InChI

1S/C21H26N2O7/c1-12(2)30-21(25)18-14(4)22-13(3)17(20(24)29-10-9-28-5)19(18)15-7-6-8-16(11-15)23(26)27/h6-8,11-12,19,22H,9-10H2,1-5H3

InChI key

UIAGMCDKSXEBJQ-UHFFFAOYSA-N

基因信息

human ... CACNA1C(775) , CACNA1D(776) , CACNA1F(778) , CACNA1S(779) , NR3C2(4306)

正在寻找类似产品? 访问 产品对比指南

相关类别

比较类似商品

查看完整比较结果

显示差异

1 of 4

此商品
PHR1075SML1493E2535
西咪替丁

C4522

西咪替丁

西咪替丁 Pharmaceutical Secondary Standard; Certified Reference Material

PHR1075

西咪替丁

Suprafenacine ≥98% (HPLC)

SML1493

Suprafenacine

Eprosartan mesylate ≥98% (HPLC)

E2535

Eprosartan mesylate

form

powder

form

-

form

powder

form

powder

Quality Level

200

Quality Level

300

Quality Level

-

Quality Level

100

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

room temp

originator

GlaxoSmithKline

originator

-

originator

-

originator

Abbott

Gene Information

human ... ABCB1(5243), CYP1A2(1544), CYP3A4(1576), HRH2(3274), SLC9A2(6549), SLC9A5(6553)
mouse ... Abcb1a(18671), Abcb1b(18669)
rat ... Slc9a1(24782), Slc9a3(24784), Slc9a5(192215)

Gene Information

human ... HRH2(3274)

Gene Information

-

Gene Information

human ... AGTR1(185)

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Nimodipine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包装

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他说明

Sales restrictions may apply.

相关产品

产品编号
说明
价格

N0850010

尼莫地平杂质A, European Pharmacopoeia (EP) Reference Standard

1463870

Nimodipine Related Compound A, United States Pharmacopeia (USP) Reference Standard

1463858

尼莫地平, United States Pharmacopeia (USP) Reference Standard

1463869

Nimodipine Related Compound B, United States Pharmacopeia (USP) Reference Standard

Y0001784

尼莫地平, European Pharmacopoeia (EP) Reference Standard

BP651

尼莫地平, British Pharmacopoeia (BP) Reference Standard

75161

Bis(1-methylethyl) 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland

BP943

Nimodipine impurity A, British Pharmacopoeia (BP) Reference Standard

象形图

Exclamation mark
GHS07

警示用语：

Warning

危险声明

H302

危险分类

Acute Tox. 4 Oral

储存分类代码

11 - Combustible Solids

WGK

WGK 1

闪点(°F)

Not applicable

闪点(°C)

Not applicable

  • 技术规格说明书

    • 历史批次信息供参考:

    分析证书(COA)

    Lot/Batch Number

    It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

    如需帮助，请联系 客户支持

    已有该产品？

    在文件库中查找您最近购买产品的文档。

    访问文档库

    J Horn et al.
    Stroke, 32(10), 2433-2438 (2001-10-06)
    Based on the results of animal experiments, clinical trials were performed with nimodipine, which did not demonstrate a beneficial effect on outcome after stroke. The aim of this study was to determine whether the evidence from animal experiments with nimodipine
    Potential interactions between nimodipine and adrenal hormones.
    R L Isaacson et al.
    Annals of the New York Academy of Sciences, 765, 134-142 (1995-09-15)
    W Mück et al.
    Die Pharmazie, 49(2-3), 130-139 (1994-02-01)
    The analytical test procedures currently established for the determination of the dihydropyridine calcium antagonist nimodipine in biological fluids are presented. Method of choice which has been dominantly used in pharmacokinetic investigations and drug interaction studies is gas chromatography with electron-capture
    Daniele Tomassoni et al.
    Clinical and experimental hypertension (New York, N.Y. : 1993), 30(8), 744-766 (2008-11-21)
    Nimodipine is a 1,4-dihydropyridine-derivative Ca(2+)-channel blocker developed approximately 30 years ago. It is highly lipophilic, crosses the blood-brain barrier, and reaches brain and cerebrospinal fluid. Early treatment with nimodipine reduces the severity of neurological deficits resulting from vasospasm in subarachnoid
    Clark A Rosen et al.
    Muscle & nerve, 50(1), 114-118 (2014-03-19)
    Nimodipine has been shown to be beneficial for recovery from acute vocal fold paralysis (AVFP) in an animal model. prospective, open-label trial of patients with AVFP was performed using nimodipine. Consecutive patients were evaluated and offered nimodipine therapy. Fifty-three patients
    查看所有相关文献

    我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

    联系客户支持